Core Viewpoint - Far East Horizon's performance is below expectations, with a projected revenue decline of 5% to 35.8 billion yuan in 2025 and a slight net profit increase of 1% to 3.9 billion yuan, primarily due to ongoing pressure in the construction and development sector and cautious provisioning amid rapid expansion in inclusive finance [1][2] Financial Performance - Financial business revenue is expected to grow by 4.5% to 22.7 billion yuan in 2025, accounting for 63% of total revenue, driven by a 3% increase in interest income to 21.8 billion yuan and a significant 66% rise in consulting fee income to 900 million yuan [1] - The net interest margin is projected to expand by 34 basis points to 4.83%, with the average asset yield increasing by 4.9 percentage points to 15.71% [1] Industry Operations - The overall industry operations are under pressure, with a projected revenue decline of 18% to 13.3 billion yuan in 2025, and a 6 percentage point decrease in revenue share to 37% [2] - The construction and development segment is expected to see a 19% revenue decline to 9.4 billion yuan, with adjusted net profit dropping by 84% to 150 million yuan, prompting a shift towards overseas markets [2] Profit Forecast and Valuation - The earnings forecast for 2026 has been reduced by 13% to 4.1 billion yuan, with a new forecast for 2027 set at 4.3 billion yuan [2] - The company is currently trading at 0.6x P/B for both 2026 and 2027, with a target price maintained at 8.8 HKD, indicating a potential upside of 15% [2]

Core Viewpoint - CICC has downgraded the earnings forecast for Far East Horizon (03360) for 2026 by 13% to 4.1 billion HKD, while introducing a forecast of 4.3 billion HKD for 2027, citing ongoing operational pressures and increased provisions due to the expansion of inclusive finance business [1][9]. Financial Performance - Far East Horizon's revenue for 2025 is expected to decline by 5% to 35.8 billion HKD, with net profit attributable to shareholders increasing by 1% to 3.9 billion HKD, reflecting a slight underperformance against expectations due to pressures on the construction and development segment and cautious provisioning amid rapid expansion of inclusive finance [2][10]. - The company's financial business revenue is projected to grow by 4.5% to 22.7 billion HKD in 2025, accounting for 63% of total revenue, driven by a 3% increase in interest income to 21.8 billion HKD and a 66% rise in consulting fee income to 0.9 billion HKD [3][11]. - The net interest margin is expected to expand by 34 basis points to 4.83%, with the average asset yield increasing by 4.9 percentage points to 15.71% [3][12]. Industry Operations - The overall performance of the industry remains under pressure, with the operational revenue expected to decline by 18% to 13.3 billion HKD, representing a 6 percentage point decrease in revenue share to 37% [4][13]. - The construction and development segment is anticipated to see a 19% drop in revenue to 9.4 billion HKD, with adjusted net profit decreasing by 84% to 0.15 billion HKD, prompting a strategic shift towards overseas markets where revenue is expected to increase by 360% [6][13]. - The health segment is projected to experience a 13% decline in revenue to 3.6 billion HKD, with net profit down by 64% to 0.08 billion HKD, as the company continues to upgrade its strategic focus towards a "medical + health" integrated service model [6][13].

Core Viewpoint - Guotai Junan Securities maintains a "Buy" rating for Far East Horizon (03360), citing stable financial operations and expected growth in overseas contributions from Hongxin Jianfa, with projected net profit growth rates of 4%/5%/5% from 2026 to 2028 [1] Financial Performance Summary - In 2025, Far East Horizon reported total revenue of 35.785 billion yuan, a decrease of 5.2% year-on-year, primarily due to a decline in industrial operation revenue; net profit attributable to shareholders was 3.889 billion yuan, an increase of 0.7% year-on-year; the weighted average return on equity was 7.71%, down 0.09 percentage points, with performance in line with expectations [1] Interest Income and Asset Quality - Interest income grew by 3% year-on-year to 21.807 billion yuan, accounting for 61% of total revenue; average balance of interest-earning assets increased by 1.4% to 266.4 billion yuan, with inclusive finance business expanding by 55% to 22.5 billion yuan; net interest margin increased by 0.39 percentage points to 4.39%, driven by a rise in asset yield by 0.12 percentage points to 8.18% and a decrease in funding costs by 0.27 percentage points [2] - As of the end of 2025, the non-performing loan ratio was 1.03%, down 0.04 percentage points year-on-year; the "30+ days overdue" ratio decreased by 0.08 percentage points to 0.82%, with a provision coverage ratio of 228%, remaining stable year-on-year [2] Industrial Operation Revenue - Industrial operation revenue decreased by 18% year-on-year, accounting for 37% of total revenue; Hongxin Jianfa reported revenue of 9.359 billion yuan, down 19% year-on-year, mainly due to declining domestic equipment rental prices and a contraction in material-related businesses; overseas business grew rapidly, with 562 service outlets globally by the end of 2025, including 77 overseas outlets across 7 countries, contributing approximately 15% to revenue and about 92% to profits [3] Dividend Distribution - The company declared an interim dividend of 0.25 HKD per share and a proposed final dividend of 0.31 HKD per share, totaling 0.56 HKD per share, corresponding to a dividend payout ratio of approximately 61% [4]

Core Viewpoint - Far East Horizon (03360.HK) reported a revenue of RMB 35.785 billion for the fiscal year 2025, a decrease of 5.20% year-on-year, while net profit attributable to ordinary shareholders was RMB 3.889 billion, an increase of 0.67% year-on-year, with an average return on equity of 7.71% and basic earnings per share of RMB 0.87. A final dividend of HKD 0.31 per share is proposed. As of the end of 2025, total assets reached RMB 370.961 billion, an increase of 2.93% from the previous year [1]. Financial Services Segment - The financial services segment achieved a total revenue of RMB 22.676 billion, representing a year-on-year growth of 4.47%. Traditional business leveraged resource and mechanism advantages to provide high-quality services to top clients while maintaining asset quality and interest margin [2]. - The inclusive finance sector focused on economically developed regions, achieving rapid growth in asset scale and interest income, with a strict approach to bad debt recognition and write-offs to ensure operational safety. As of the end of 2025, net interest-earning assets amounted to RMB 272.047 billion, a growth of 4.38% year-on-year, with a non-performing asset ratio of 1.03% and a net interest margin of 4.39% [2]. Industrial Operations Segment - The industrial operations segment generated a total revenue of RMB 13.284 billion, accounting for 36.94% of total revenue, maintaining a diversified financial structure. Hongxin Jianda, a leading equipment operation service provider, faced performance pressure due to market conditions but continued to optimize asset allocation [3]. - The overseas market expanded with a focus on local market penetration, aiming to become a world-class equipment operation service provider. As of the end of 2025, Hongxin Jianda managed approximately 200,000 aerial work platforms and 188,000 tons of material assets, with 485 service outlets in China and 77 overseas, covering several countries [3]. - Hongxin Health optimized its management model, operating 25 hospitals, with total revenue of RMB 3.572 billion and a net profit of RMB 0.083 billion in 2025, contributing positively to overall profitability [3].

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical and biotechnology industry [1]. Core Insights - The pharmaceutical sector has underperformed compared to the broader market, with a decline of 2.78% over the past week, while the Shanghai Composite Index fell by 1.07% [10]. - The report highlights that 42 companies will be included in the Hong Kong Stock Connect on March 9, 2026, with 13 from the biopharmaceutical and healthcare sectors, which is expected to enhance trading liquidity and shareholder structure [4][11]. - The current valuation of the pharmaceutical sector is 33.3 times PE based on 2026 earnings forecasts, representing a 26% premium over the overall A-share market (excluding financials) [4][11]. Summary by Sections 1. Industry Performance - The pharmaceutical sector ranks 17th among 31 primary sub-industries, with specific sub-sectors like medical services and biological products experiencing significant declines [10]. - Year-to-date, the pharmaceutical sector has yielded a return of 0.10%, lagging behind the Shanghai Composite Index's return of 0.66% [4][10]. 2. Market Dynamics - The report notes that the pharmaceutical sector's performance has been affected by various factors, including recent policy adjustments and market sentiment [4][10]. - The report emphasizes the ongoing innovation in domestic pharmaceutical companies, which is expected to drive future growth [4]. 3. Valuation Metrics - The TTM (Trailing Twelve Months) PE ratio for the pharmaceutical sector is currently at 30.5, which is below the historical average of 34.9 [4][11]. - The report indicates that the pharmaceutical sector's valuation is relatively attractive compared to the overall market, suggesting potential investment opportunities [4][11]. 4. Key Companies to Watch - The report identifies several companies to focus on, including Aidi Pharmaceutical, WuXi Biologics, and others, which are expected to benefit from the current market dynamics [4][5].

Core Viewpoint - The healthcare index (980016) experienced a rise of 1.01% on March 5, closing at 5804.4 points, with a total transaction volume of 9.822 billion yuan and a turnover rate of 0.35% [1] Group 1: Index Performance - On the same day, 36 constituent stocks of the healthcare index increased in value, with Rongchang Biological leading the gains at 4.86% [1] - Conversely, 12 stocks declined, with Ailis leading the losses at 3.61% [1] Group 2: Capital Flow - The net outflow of main funds from the healthcare index constituents totaled 229 million yuan, while retail funds saw a net outflow of 61.5482 million yuan [2] - In contrast, there was a net inflow of 290 million yuan from speculative funds [2]

Group 1 - The Beijing Municipal Economic and Information Bureau has released the implementation guidelines for the 2026 development projects of high-precision industries and support funds for small and medium-sized enterprises, with 24 areas eligible for financial support, including integrated circuit design and product first-round wafer tape-out [1] - The highest amount of strategic project loan interest subsidies can reach 50 million yuan per project annually, aimed at encouraging enterprises to utilize bank loans for significant strategic projects [1] - The focus areas for support this year include industrial innovation transformation, quality improvement, and safeguarding enterprise growth [1] Group 2 - In the area of industrial innovation transformation, various key industries are covered, such as integrated circuit design, which can receive rewards up to 30 million yuan for multiple project wafer tape-out [2] - The medical health industry can also receive rewards for innovative drugs and medical devices, with a maximum of 30 million yuan per enterprise for scaling up applications [2] - The guidelines support digital transformation, with rewards for platform service providers and benchmark enterprises that help local manufacturing achieve digital transformation [2] Group 3 - Green and low-carbon development projects can receive rewards up to 30 million yuan for enterprises undertaking green transformation [3] - Support is also available for the renovation of old factory buildings, with a maximum reward of 10 million yuan per project, and for industrial tourism projects, which can receive up to 1 million yuan [3] - The "Win the Future" growth plan targets early-stage potential enterprises, providing support up to 10 million yuan through training and public roadshows [3]

Group 1 - The core viewpoint of the articles emphasizes the transformation brought by digitalization in both industrial and healthcare sectors, showcasing how technology enhances efficiency and quality control [1][2][6] - Tang'an Electric Technology Co., Ltd. has implemented an intelligent management system that utilizes AI for quality control, resulting in a stable record of zero accidents in electrical testing and a sales revenue exceeding 30 million yuan last year [1] - The city of Xianyang has completed the digital transformation of 100 enterprises and is fostering multiple smart factories, indicating a shift from a passive to an active approach in digital adoption among businesses [2] Group 2 - In the healthcare sector, the introduction of the "Imaging Cloud" platform has significantly reduced the need for repeat examinations, with an estimated 120 million fewer repeat checks annually due to improved data accessibility across hospitals [5] - The "Imaging Cloud" platform has connected 11 medical institutions, achieving full coverage of six tertiary hospitals and pilot connections with some secondary hospitals, facilitating the sharing of 710,000 imaging data [5] - Xianyang has been recognized as a pilot city for small and medium-sized enterprise digital transformation and has built over 12,000 5G base stations, positioning itself among the top cities in the national digital economy rankings [6]

Group 1: National Development Goals - The 14th Five-Year Plan and the 2035 vision aim to achieve significant progress in economy, technology, and national strength, targeting a per capita GDP that meets the standards of moderately developed countries and increasing the middle-income population [3] - By 2030, urbanization rate is expected to approach 70%, with urban clusters like Beijing-Tianjin-Hebei, Yangtze River Delta, and Guangdong-Hong Kong-Macau Greater Bay Area becoming more integrated [3][15] - The goal is to enhance the quality of life for ordinary citizens through these developments, not just focusing on numerical targets [3] Group 2: Technological Advancements - The focus on technological independence and self-reliance has led to increased funding support, transforming companies from followers to leaders, particularly in the telecommunications sector with plans for 6G by 2030 [5] - Robotics technology is expected to achieve significant breakthroughs by 2027, stabilizing supply chains and enhancing production capabilities [5] - AI is projected to become a core driver of economic growth by 2035, with over 90% of economic activities being AI-driven by 2030 [13] Group 3: Space Exploration - China's space program is on track for significant milestones, including sending humans to the moon by 2030 and establishing a lunar base by 2035 [7] - The Tianwen-3 Mars exploration mission is set to return soil samples to Earth by 2031, showcasing China's advancements in space technology [7] Group 4: Energy Transition - The National Energy Administration has set a target for non-fossil energy to account for 25% of energy consumption by 2030, with a focus on increasing the share of wind and solar energy [9] - The transition to clean energy is expected to enhance environmental quality and create job opportunities while promoting economic growth [9] Group 5: Education and Health - By 2035, the national action plan aims to strengthen the education system, expanding access to quality education and increasing the enrollment rates for higher education [11] - Improvements in the healthcare system are projected to increase life expectancy to 79 years by 2030, with a focus on preventive measures and resource allocation [9][11]

Core Viewpoint - The article highlights the successful integration of Ant Group's health application "Ant Fu" into the 2026 Spring Festival Gala, emphasizing its growing importance in the health sector as consumer awareness of health increases significantly in China [3][7]. Group 1: Ant Fu's Market Positioning - Ant Fu was featured in a skit during the Spring Festival Gala, effectively promoting its brand and value proposition to a vast audience [3]. - According to Accenture's research, the importance of health to Chinese consumers rose from 78% in 2021 to 87% in 2025, indicating a strong trend towards health awareness [3]. - The application has seen a surge in downloads, ranking first on the Apple App Store for three consecutive days, driven by the trend of young people installing the app for their parents during the Spring Festival [3][4]. Group 2: Features and User Engagement - Ant Fu launched a "Senior Mode" before the Spring Festival, designed to simplify usage for older adults with features like large fonts, default voice broadcasting, and dialect support [3]. - The app connects users with over 30,000 real doctors and 5,000 hospitals across China, providing a comprehensive range of health services from inquiries to digital medical consultations [4]. - The app also features a "Famous Doctor AI Avatar" program, allowing users in rural areas to consult with top medical experts conveniently [4]. Group 3: Promotional Activities - On the day of the Spring Festival, Ant Fu announced a "Health Fortune" red envelope campaign, offering new users a 16.8 yuan Alipay red envelope, symbolizing health and good fortune for the new year [5]. - The article emphasizes the trend of using technology to enhance family health, reflecting a cultural shift towards prioritizing health in the new year [7].